Nonsteroid immunomodulating pharmaceuticals have been investigated in the treatmentof COVID-19 because elevation in inflammatory cytokines, including interleukin(IL)-6 and tumor necrosis factor α, was correlated with viral replication, severityof illness, and outcome, including mortality.7,8 Tocilizumab, a recombinanthumanized anti-human IL-6 receptor monoclonal antibody, has been shown to have arole in the treatment of COVID-19; however, the optimal timing and dosage areunknown.9, -11. The gene discussed is TNF; the disease is COVID-19.